This is a multi-center, expanded access protocol to provide access to the investigational product, abrocitinib, to adolescent and adult patients with moderate to severe atopic dermatitis who have inadequate treatment options with available and approved medicated topical and systemic therapies and who are otherwise ineligible for participation in clinical studies with abrocitinib.
This is a multi-center expanded access protocol (EAP) for the treatment of up to approximately 500 adult and adolescent (defined as age < 18 years) patients with moderate to severe atopic dermatitis for whom standard, approved medicated topical and systemic treatment options are inadequate and who would be suitable candidates for a trial of abrocitinib for potential treatment of moderate to severe atopic dermatitis. The study will also collect safety and exploratory efficacy data. Participants who meet the inclusion criteria and none of the exclusion criteria may be enrolled into the EAP to receive open-label oral treatment with abrocitinib.
Drug: abrocitinib
Participants will receive abrocitinib 100 mg or 200 mg orally once a day as directed by the investigator's clinical judgement
Inclusion Criteria: - 12 years of age or older - Clinical diagnosis of chronic atopic dermatitis for at least 6 months - Inadequate treatment options with available, approved medicated topical and systemic therapies for moderate to severe atopic dermatitis - Moderate to severe atopic dermatitis as indicated by at least one of the following: IGA ≥3; EASI ≥16 - Not eligible for participation in any ongoing clinical trial of abrocitinib, including lack of access due to geographical limitations
Exclusion Criteria: - Medical, psychiatric, or laboratory abnormality that may increase the risk associated with study participation - Medical history including thrombocytopenia, coagulopathy or platelet dysfunction, malignancies, current or history of certain infections, lymphoproliferative disorders and other medical conditions at the discretion of the investigator - Require treatment with prohibited medications during the study - Discontinued prior treatment with any systemic JAK inhibitor due to safety or tolerability issues - 12 to
Cahaba Dermatology and Skin Health Center
Birmingham, Alabama, 35244
Antelope Valley Clinical Trials
Lancaster, California, 93534
Allergy & Asthma Care Center
Long Beach, California, 90808
ACRC Studies
San Diego, California, 92119
Palm Beach Dermatology
Delray Beach, Florida, 33484
Skin Care Research
Hollywood, Florida, 33021
L&C Professional Medical Research Institute
Miami, Florida, 33144
Sarasota Clinical Research
Sarasota, Florida, 34239
Precision Clinical Research
Sunrise, Florida, 33351
Dundee Dermatology
West Dundee, Illinois, 60118
Qualmedica Research, LLC
Evansville, Indiana, 47715
Bluegrass Allergy Research
Lexington, Kentucky, 40509
Respiratory Medicine Research Institute of Michigan, PLC
Ypsilanti, Michigan, 48197
Bexley Dermatology Research
Bexley, Ohio, 43209
Hightower Clinical Trial Services - Lam Dermatology
Norman, Oklahoma, 73072
Health Concepts
Rapid City, South Dakota, 57702
Clinical Neuroscience Solutions, Inc. dba CNS Healthcare
Memphis, Tennessee, 38119
Center for Clinical Studies, LTD. LLP
Houston, Texas, 77004
Houston Medical Imaging
Houston, Texas, 77072
West Virginia Research Institute
Morgantown, West Virginia, 26505
Pfizer CT.gov Call Center
1-800-718-1021
ClinicalTrials.gov_Inquiries@pfizer.com
Pfizer CT.gov Call Center
Study Director
Pfizer